TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

IPSEN - Buy-back programme - Art 5 of MAR - Week 43 - 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
IPSEN - Buy-back programme - Art 5 of MAR - Week 43 - 2025

Ipsen reported 12.1% sales growth in the first nine months of 2025 and announced plans to acquire ImCheck Therapeutics to expand its oncology leadership, focusing on the clinical-stage program ICT01 for acute myeloid leukemia.

Insights
IPSEY   positive

Strong sales growth of 12.1%, successful performance of key products like Iqirvo®, Bylvay® and Somatuline®, and strategic acquisition of ImCheck Therapeutics to strengthen oncology pipeline